nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—breast cancer—colon cancer	0.844	1	CtDrD
Fulvestrant—NR1H4—bile—colon cancer	0.0173	0.312	CbGeAlD
Fulvestrant—NR1H4—gall bladder—colon cancer	0.0048	0.0867	CbGeAlD
Fulvestrant—NR1H4—renal system—colon cancer	0.0023	0.0416	CbGeAlD
Fulvestrant—NR1H4—digestive system—colon cancer	0.00189	0.0341	CbGeAlD
Fulvestrant—ESRRA—renal system—colon cancer	0.00176	0.0318	CbGeAlD
Fulvestrant—ESR1—blood vessel—colon cancer	0.00161	0.029	CbGeAlD
Fulvestrant—EPHX2—vagina—colon cancer	0.00146	0.0263	CbGeAlD
Fulvestrant—ESRRA—digestive system—colon cancer	0.00145	0.0261	CbGeAlD
Fulvestrant—NR1H4—liver—colon cancer	0.00141	0.0254	CbGeAlD
Fulvestrant—ESRRA—bone marrow—colon cancer	0.00133	0.0241	CbGeAlD
Fulvestrant—ESRRA—vagina—colon cancer	0.00128	0.0231	CbGeAlD
Fulvestrant—EPHX2—liver—colon cancer	0.00123	0.0222	CbGeAlD
Fulvestrant—ESR2—epithelium—colon cancer	0.00114	0.0206	CbGeAlD
Fulvestrant—ESR2—smooth muscle tissue—colon cancer	0.0011	0.0198	CbGeAlD
Fulvestrant—NR1H4—lymph node—colon cancer	0.00108	0.0195	CbGeAlD
Fulvestrant—ESRRA—liver—colon cancer	0.00108	0.0195	CbGeAlD
Fulvestrant—ESR2—renal system—colon cancer	0.00106	0.0191	CbGeAlD
Fulvestrant—Gastrointestinal symptom NOS—Fluorouracil—colon cancer	0.00101	0.0207	CcSEcCtD
Fulvestrant—ESR1—embryo—colon cancer	0.000958	0.0173	CbGeAlD
Fulvestrant—EPHX2—lymph node—colon cancer	0.000943	0.017	CbGeAlD
Fulvestrant—ESR2—lymphoid tissue—colon cancer	0.000879	0.0159	CbGeAlD
Fulvestrant—ESR2—digestive system—colon cancer	0.000868	0.0157	CbGeAlD
Fulvestrant—ESRRA—lymph node—colon cancer	0.000826	0.0149	CbGeAlD
Fulvestrant—ESR1—epithelium—colon cancer	0.000782	0.0141	CbGeAlD
Fulvestrant—ESR2—vagina—colon cancer	0.000767	0.0138	CbGeAlD
Fulvestrant—ESR1—smooth muscle tissue—colon cancer	0.000753	0.0136	CbGeAlD
Fulvestrant—ESR1—renal system—colon cancer	0.000725	0.0131	CbGeAlD
Fulvestrant—Vasodilation—Irinotecan—colon cancer	0.000707	0.0145	CcSEcCtD
Fulvestrant—Vasodilation procedure—Irinotecan—colon cancer	0.000707	0.0145	CcSEcCtD
Fulvestrant—Accidental injury—Irinotecan—colon cancer	0.000702	0.0144	CcSEcCtD
Fulvestrant—Cough increased—Irinotecan—colon cancer	0.000679	0.0139	CcSEcCtD
Fulvestrant—Bone pain—Vincristine—colon cancer	0.000666	0.0136	CcSEcCtD
Fulvestrant—Blood bilirubin increased—Irinotecan—colon cancer	0.000657	0.0134	CcSEcCtD
Fulvestrant—ESR2—liver—colon cancer	0.000647	0.0117	CbGeAlD
Fulvestrant—Musculoskeletal pain—Vincristine—colon cancer	0.000646	0.0132	CcSEcCtD
Fulvestrant—Inflammation—Fluorouracil—colon cancer	0.000614	0.0126	CcSEcCtD
Fulvestrant—ESR1—lymphoid tissue—colon cancer	0.000602	0.0109	CbGeAlD
Fulvestrant—ESR1—digestive system—colon cancer	0.000595	0.0107	CbGeAlD
Fulvestrant—Vaginal haemorrhage—Capecitabine—colon cancer	0.000562	0.0115	CcSEcCtD
Fulvestrant—ESR1—vagina—colon cancer	0.000525	0.00948	CbGeAlD
Fulvestrant—Hepatic failure—Vincristine—colon cancer	0.000515	0.0105	CcSEcCtD
Fulvestrant—Injection site pain—Capecitabine—colon cancer	0.000509	0.0104	CcSEcCtD
Fulvestrant—Vaginal discharge—Methotrexate—colon cancer	0.000509	0.0104	CcSEcCtD
Fulvestrant—ESR2—lymph node—colon cancer	0.000496	0.00895	CbGeAlD
Fulvestrant—Injury—Irinotecan—colon cancer	0.000491	0.01	CcSEcCtD
Fulvestrant—Pain in extremity—Vincristine—colon cancer	0.000463	0.00948	CcSEcCtD
Fulvestrant—ESR1—liver—colon cancer	0.000443	0.008	CbGeAlD
Fulvestrant—Blood bilirubin increased—Capecitabine—colon cancer	0.00044	0.009	CcSEcCtD
Fulvestrant—Bone pain—Capecitabine—colon cancer	0.000434	0.00889	CcSEcCtD
Fulvestrant—Inflammation—Capecitabine—colon cancer	0.000429	0.00878	CcSEcCtD
Fulvestrant—Injection site reaction—Capecitabine—colon cancer	0.000413	0.00846	CcSEcCtD
Fulvestrant—CYP3A4—renal system—colon cancer	0.000404	0.0073	CbGeAlD
Fulvestrant—Depression—Vincristine—colon cancer	0.000356	0.00728	CcSEcCtD
Fulvestrant—Sweating—Vincristine—colon cancer	0.000342	0.007	CcSEcCtD
Fulvestrant—ESR1—lymph node—colon cancer	0.00034	0.00613	CbGeAlD
Fulvestrant—Hepatic failure—Capecitabine—colon cancer	0.000336	0.00688	CcSEcCtD
Fulvestrant—Sweating—Irinotecan—colon cancer	0.000333	0.00682	CcSEcCtD
Fulvestrant—Infestation NOS—Fluorouracil—colon cancer	0.000333	0.00681	CcSEcCtD
Fulvestrant—Infestation—Fluorouracil—colon cancer	0.000333	0.00681	CcSEcCtD
Fulvestrant—CYP3A4—digestive system—colon cancer	0.000332	0.00599	CbGeAlD
Fulvestrant—Hepatic enzyme increased—Methotrexate—colon cancer	0.000327	0.0067	CcSEcCtD
Fulvestrant—Urinary tract infection—Fluorouracil—colon cancer	0.000324	0.00662	CcSEcCtD
Fulvestrant—Hot flush—Capecitabine—colon cancer	0.000323	0.0066	CcSEcCtD
Fulvestrant—Menopausal symptoms—Capecitabine—colon cancer	0.00032	0.00655	CcSEcCtD
Fulvestrant—Inflammation—Methotrexate—colon cancer	0.000319	0.00653	CcSEcCtD
Fulvestrant—Connective tissue disorder—Vincristine—colon cancer	0.000315	0.00644	CcSEcCtD
Fulvestrant—Haemoglobin—Irinotecan—colon cancer	0.000314	0.00642	CcSEcCtD
Fulvestrant—Haemorrhage—Irinotecan—colon cancer	0.000312	0.00639	CcSEcCtD
Fulvestrant—Arthritis—Capecitabine—colon cancer	0.000311	0.00636	CcSEcCtD
Fulvestrant—Connective tissue disorder—Irinotecan—colon cancer	0.000307	0.00628	CcSEcCtD
Fulvestrant—Pain in extremity—Capecitabine—colon cancer	0.000302	0.00618	CcSEcCtD
Fulvestrant—Haemoglobin—Fluorouracil—colon cancer	0.0003	0.00615	CcSEcCtD
Fulvestrant—Haemorrhage—Fluorouracil—colon cancer	0.000299	0.00612	CcSEcCtD
Fulvestrant—Pharyngitis—Fluorouracil—colon cancer	0.000297	0.00607	CcSEcCtD
Fulvestrant—Angiopathy—Vincristine—colon cancer	0.000291	0.00595	CcSEcCtD
Fulvestrant—Angiopathy—Irinotecan—colon cancer	0.000283	0.00579	CcSEcCtD
Fulvestrant—Immune system disorder—Irinotecan—colon cancer	0.000282	0.00577	CcSEcCtD
Fulvestrant—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.000274	0.0053	CbGpPWpGaD
Fulvestrant—Breast disorder—Capecitabine—colon cancer	0.000273	0.00558	CcSEcCtD
Fulvestrant—Back pain—Vincristine—colon cancer	0.00027	0.00552	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000265	0.00513	CbGpPWpGaD
Fulvestrant—Back pain—Irinotecan—colon cancer	0.000263	0.00538	CcSEcCtD
Fulvestrant—Influenza—Capecitabine—colon cancer	0.000261	0.00534	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CHST5—colon cancer	0.000261	0.00505	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ODC1—colon cancer	0.000261	0.00505	CbGpPWpGaD
Fulvestrant—Anaemia—Vincristine—colon cancer	0.000258	0.00528	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—CA7—colon cancer	0.000251	0.00487	CbGpPWpGaD
Fulvestrant—Anaemia—Irinotecan—colon cancer	0.000251	0.00514	CcSEcCtD
Fulvestrant—Vertigo—Vincristine—colon cancer	0.000251	0.00513	CcSEcCtD
Fulvestrant—Hepatic failure—Methotrexate—colon cancer	0.00025	0.00512	CcSEcCtD
Fulvestrant—Leukopenia—Vincristine—colon cancer	0.00025	0.00511	CcSEcCtD
Fulvestrant—CYP3A4—liver—colon cancer	0.000247	0.00446	CbGeAlD
Fulvestrant—Vertigo—Irinotecan—colon cancer	0.000244	0.00499	CcSEcCtD
Fulvestrant—Leukopenia—Irinotecan—colon cancer	0.000243	0.00498	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000241	0.00467	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—PPARG—colon cancer	0.000241	0.00466	CbGpPWpGaD
Fulvestrant—Anaemia—Fluorouracil—colon cancer	0.00024	0.00492	CcSEcCtD
Fulvestrant—Myalgia—Vincristine—colon cancer	0.000238	0.00486	CcSEcCtD
Fulvestrant—Cough—Irinotecan—colon cancer	0.000237	0.00485	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—KRAS—colon cancer	0.000237	0.00458	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MSH6—colon cancer	0.000236	0.00457	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—HNF4A—colon cancer	0.000236	0.00456	CbGpPWpGaD
Fulvestrant—NR1H4—PPARA activates gene expression—PPARG—colon cancer	0.000234	0.00453	CbGpPWpGaD
Fulvestrant—Leukopenia—Fluorouracil—colon cancer	0.000233	0.00477	CcSEcCtD
Fulvestrant—Infestation—Capecitabine—colon cancer	0.000233	0.00476	CcSEcCtD
Fulvestrant—Infestation NOS—Capecitabine—colon cancer	0.000233	0.00476	CcSEcCtD
Fulvestrant—Depression—Capecitabine—colon cancer	0.000232	0.00475	CcSEcCtD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.000229	0.00444	CbGpPWpGaD
Fulvestrant—Infection—Vincristine—colon cancer	0.000226	0.00463	CcSEcCtD
Fulvestrant—Urinary tract infection—Capecitabine—colon cancer	0.000226	0.00463	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—CCND1—colon cancer	0.000223	0.00433	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Vincristine—colon cancer	0.000223	0.00457	CcSEcCtD
Fulvestrant—Myalgia—Fluorouracil—colon cancer	0.000222	0.00453	CcSEcCtD
Fulvestrant—Chest pain—Fluorouracil—colon cancer	0.000222	0.00453	CcSEcCtD
Fulvestrant—Infection—Irinotecan—colon cancer	0.00022	0.00451	CcSEcCtD
Fulvestrant—Hyperhidrosis—Vincristine—colon cancer	0.00022	0.0045	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Capecitabine—colon cancer	0.00022	0.0045	CcSEcCtD
Fulvestrant—Nervous system disorder—Irinotecan—colon cancer	0.000217	0.00445	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—PIK3CA—colon cancer	0.000217	0.00421	CbGpPWpGaD
Fulvestrant—Anorexia—Vincristine—colon cancer	0.000217	0.00444	CcSEcCtD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000216	0.00418	CbGpPWpGaD
Fulvestrant—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000215	0.00415	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Irinotecan—colon cancer	0.000214	0.00439	CcSEcCtD
Fulvestrant—Anorexia—Irinotecan—colon cancer	0.000211	0.00433	CcSEcCtD
Fulvestrant—Infection—Fluorouracil—colon cancer	0.000211	0.00432	CcSEcCtD
Fulvestrant—Haemoglobin—Capecitabine—colon cancer	0.00021	0.0043	CcSEcCtD
Fulvestrant—ESRRA—PPARA activates gene expression—EP300—colon cancer	0.00021	0.00406	CbGpPWpGaD
Fulvestrant—Haemorrhage—Capecitabine—colon cancer	0.000209	0.00427	CcSEcCtD
Fulvestrant—Hepatitis—Capecitabine—colon cancer	0.000209	0.00427	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CHST5—colon cancer	0.000208	0.00403	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ODC1—colon cancer	0.000208	0.00403	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Fluorouracil—colon cancer	0.000208	0.00426	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Vincristine—colon cancer	0.000207	0.00424	CcSEcCtD
Fulvestrant—Pharyngitis—Capecitabine—colon cancer	0.000207	0.00424	CcSEcCtD
Fulvestrant—Insomnia—Vincristine—colon cancer	0.000206	0.00421	CcSEcCtD
Fulvestrant—Oedema peripheral—Capecitabine—colon cancer	0.000206	0.00421	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—EP300—colon cancer	0.000206	0.00398	CbGpPWpGaD
Fulvestrant—Connective tissue disorder—Capecitabine—colon cancer	0.000205	0.0042	CcSEcCtD
Fulvestrant—ESRRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.000205	0.00397	CbGpPWpGaD
Fulvestrant—Paraesthesia—Vincristine—colon cancer	0.000204	0.00418	CcSEcCtD
Fulvestrant—Breast disorder—Methotrexate—colon cancer	0.000203	0.00416	CcSEcCtD
Fulvestrant—Anorexia—Fluorouracil—colon cancer	0.000202	0.00414	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—colon cancer	0.000202	0.00391	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—HRAS—colon cancer	0.000201	0.00389	CbGpPWpGaD
Fulvestrant—Insomnia—Irinotecan—colon cancer	0.000201	0.0041	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—BCL2L1—colon cancer	0.0002	0.00387	CbGpPWpGaD
Fulvestrant—Paraesthesia—Irinotecan—colon cancer	0.000199	0.00407	CcSEcCtD
Fulvestrant—Decreased appetite—Vincristine—colon cancer	0.000198	0.00405	CcSEcCtD
Fulvestrant—Dyspnoea—Irinotecan—colon cancer	0.000198	0.00405	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Vincristine—colon cancer	0.000197	0.00402	CcSEcCtD
Fulvestrant—Fatigue—Vincristine—colon cancer	0.000196	0.00402	CcSEcCtD
Fulvestrant—Dyspepsia—Irinotecan—colon cancer	0.000195	0.00399	CcSEcCtD
Fulvestrant—Constipation—Vincristine—colon cancer	0.000195	0.00398	CcSEcCtD
Fulvestrant—Pain—Vincristine—colon cancer	0.000195	0.00398	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000193	0.00396	CcSEcCtD
Fulvestrant—Decreased appetite—Irinotecan—colon cancer	0.000193	0.00394	CcSEcCtD
Fulvestrant—Insomnia—Fluorouracil—colon cancer	0.000192	0.00393	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MSH2—colon cancer	0.000192	0.00371	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Irinotecan—colon cancer	0.000191	0.00392	CcSEcCtD
Fulvestrant—Fatigue—Irinotecan—colon cancer	0.000191	0.00391	CcSEcCtD
Fulvestrant—Paraesthesia—Fluorouracil—colon cancer	0.000191	0.0039	CcSEcCtD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—PPARG—colon cancer	0.00019	0.00368	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—BAX—colon cancer	0.00019	0.00368	CbGpPWpGaD
Fulvestrant—Pain—Irinotecan—colon cancer	0.00019	0.00388	CcSEcCtD
Fulvestrant—Constipation—Irinotecan—colon cancer	0.00019	0.00388	CcSEcCtD
Fulvestrant—Angiopathy—Capecitabine—colon cancer	0.00019	0.00388	CcSEcCtD
Fulvestrant—Dyspnoea—Fluorouracil—colon cancer	0.000189	0.00387	CcSEcCtD
Fulvestrant—Immune system disorder—Capecitabine—colon cancer	0.000189	0.00386	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000188	0.00365	CbGpPWpGaD
Fulvestrant—Dyspepsia—Fluorouracil—colon cancer	0.000187	0.00383	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Vincristine—colon cancer	0.000186	0.00381	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000185	0.00358	CbGpPWpGaD
Fulvestrant—Decreased appetite—Fluorouracil—colon cancer	0.000185	0.00378	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000183	0.00375	CcSEcCtD
Fulvestrant—Malnutrition—Capecitabine—colon cancer	0.000182	0.00372	CcSEcCtD
Fulvestrant—Pain—Fluorouracil—colon cancer	0.000182	0.00372	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Irinotecan—colon cancer	0.000181	0.00371	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000181	0.0035	CbGpPWpGaD
Fulvestrant—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000181	0.0035	CbGpPWpGaD
Fulvestrant—Abdominal pain—Vincristine—colon cancer	0.00018	0.00368	CcSEcCtD
Fulvestrant—Body temperature increased—Vincristine—colon cancer	0.00018	0.00368	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—MYC—colon cancer	0.000179	0.00347	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000178	0.00345	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—AKT1—colon cancer	0.000178	0.00344	CbGpPWpGaD
Fulvestrant—Back pain—Capecitabine—colon cancer	0.000176	0.0036	CcSEcCtD
Fulvestrant—Abdominal pain—Irinotecan—colon cancer	0.000175	0.00359	CcSEcCtD
Fulvestrant—Body temperature increased—Irinotecan—colon cancer	0.000175	0.00359	CcSEcCtD
Fulvestrant—ESR1—Estrogen signaling pathway—PIK3CA—colon cancer	0.000174	0.00337	CbGpPWpGaD
Fulvestrant—Infestation NOS—Methotrexate—colon cancer	0.000173	0.00354	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—colon cancer	0.000173	0.00354	CcSEcCtD
Fulvestrant—Depression—Methotrexate—colon cancer	0.000173	0.00353	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—HNF4A—colon cancer	0.000172	0.00333	CbGpPWpGaD
Fulvestrant—Urticaria—Fluorouracil—colon cancer	0.000169	0.00345	CcSEcCtD
Fulvestrant—Anaemia—Capecitabine—colon cancer	0.000168	0.00344	CcSEcCtD
Fulvestrant—Body temperature increased—Fluorouracil—colon cancer	0.000168	0.00344	CcSEcCtD
Fulvestrant—Hypersensitivity—Vincristine—colon cancer	0.000168	0.00343	CcSEcCtD
Fulvestrant—Sweating—Methotrexate—colon cancer	0.000166	0.0034	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—BCL2L1—colon cancer	0.000165	0.00319	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Methotrexate—colon cancer	0.000164	0.00335	CcSEcCtD
Fulvestrant—Vertigo—Capecitabine—colon cancer	0.000163	0.00334	CcSEcCtD
Fulvestrant—Hypersensitivity—Irinotecan—colon cancer	0.000163	0.00334	CcSEcCtD
Fulvestrant—Asthenia—Vincristine—colon cancer	0.000163	0.00334	CcSEcCtD
Fulvestrant—Leukopenia—Capecitabine—colon cancer	0.000163	0.00333	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	0.000162	0.00314	CbGpPWpGaD
Fulvestrant—Asthenia—Irinotecan—colon cancer	0.000159	0.00326	CcSEcCtD
Fulvestrant—Cough—Capecitabine—colon cancer	0.000159	0.00325	CcSEcCtD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000158	0.00306	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—CCND1—colon cancer	0.000158	0.00306	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Fluorouracil—colon cancer	0.000156	0.0032	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—colon cancer	0.000156	0.0032	CcSEcCtD
Fulvestrant—Diarrhoea—Vincristine—colon cancer	0.000156	0.00319	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—colon cancer	0.000155	0.00318	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—colon cancer	0.000155	0.00318	CcSEcCtD
Fulvestrant—Myalgia—Capecitabine—colon cancer	0.000155	0.00317	CcSEcCtD
Fulvestrant—Chest pain—Capecitabine—colon cancer	0.000155	0.00317	CcSEcCtD
Fulvestrant—Arthralgia—Capecitabine—colon cancer	0.000155	0.00317	CcSEcCtD
Fulvestrant—Pharyngitis—Methotrexate—colon cancer	0.000154	0.00316	CcSEcCtD
Fulvestrant—Anxiety—Capecitabine—colon cancer	0.000154	0.00316	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000154	0.00315	CcSEcCtD
Fulvestrant—NR1H4—PPARA activates gene expression—EP300—colon cancer	0.000153	0.00297	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CHST5—colon cancer	0.000152	0.00295	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ODC1—colon cancer	0.000152	0.00295	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000152	0.00295	CbGpPWpGaD
Fulvestrant—Diarrhoea—Irinotecan—colon cancer	0.000152	0.0031	CcSEcCtD
Fulvestrant—Dizziness—Vincristine—colon cancer	0.000151	0.00308	CcSEcCtD
Fulvestrant—Pruritus—Fluorouracil—colon cancer	0.00015	0.00307	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—HNF4A—colon cancer	0.00015	0.0029	CbGpPWpGaD
Fulvestrant—NR1H4—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	0.00015	0.0029	CbGpPWpGaD
Fulvestrant—Infection—Capecitabine—colon cancer	0.000147	0.00302	CcSEcCtD
Fulvestrant—Dizziness—Irinotecan—colon cancer	0.000147	0.003	CcSEcCtD
Fulvestrant—Nervous system disorder—Capecitabine—colon cancer	0.000146	0.00298	CcSEcCtD
Fulvestrant—Diarrhoea—Fluorouracil—colon cancer	0.000145	0.00297	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—EP300—colon cancer	0.000145	0.00281	CbGpPWpGaD
Fulvestrant—Vomiting—Vincristine—colon cancer	0.000145	0.00296	CcSEcCtD
Fulvestrant—Skin disorder—Capecitabine—colon cancer	0.000144	0.00295	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—SRC—colon cancer	0.000144	0.00279	CbGpPWpGaD
Fulvestrant—Rash—Vincristine—colon cancer	0.000144	0.00294	CcSEcCtD
Fulvestrant—Hyperhidrosis—Capecitabine—colon cancer	0.000143	0.00294	CcSEcCtD
Fulvestrant—Dermatitis—Vincristine—colon cancer	0.000143	0.00293	CcSEcCtD
Fulvestrant—Headache—Vincristine—colon cancer	0.000143	0.00292	CcSEcCtD
Fulvestrant—ESR1—Estrogen signaling pathway—AKT1—colon cancer	0.000142	0.00275	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	0.000142	0.00275	CbGpPWpGaD
Fulvestrant—Anorexia—Capecitabine—colon cancer	0.000141	0.00289	CcSEcCtD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000141	0.00274	CbGpPWpGaD
Fulvestrant—Angiopathy—Methotrexate—colon cancer	0.000141	0.00289	CcSEcCtD
Fulvestrant—Vomiting—Irinotecan—colon cancer	0.000141	0.00288	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—colon cancer	0.00014	0.00287	CcSEcCtD
Fulvestrant—Dizziness—Fluorouracil—colon cancer	0.00014	0.00287	CcSEcCtD
Fulvestrant—ESR1—FOXA1 transcription factor network—EP300—colon cancer	0.00014	0.00271	CbGpPWpGaD
Fulvestrant—Rash—Irinotecan—colon cancer	0.00014	0.00286	CcSEcCtD
Fulvestrant—Dermatitis—Irinotecan—colon cancer	0.00014	0.00286	CcSEcCtD
Fulvestrant—Headache—Irinotecan—colon cancer	0.000139	0.00284	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—NRAS—colon cancer	0.000139	0.00268	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000136	0.00263	CbGpPWpGaD
Fulvestrant—Malnutrition—Methotrexate—colon cancer	0.000135	0.00277	CcSEcCtD
Fulvestrant—Nausea—Vincristine—colon cancer	0.000135	0.00277	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000135	0.00277	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000135	0.00262	CbGpPWpGaD
Fulvestrant—Vomiting—Fluorouracil—colon cancer	0.000135	0.00276	CcSEcCtD
Fulvestrant—Insomnia—Capecitabine—colon cancer	0.000134	0.00275	CcSEcCtD
Fulvestrant—Rash—Fluorouracil—colon cancer	0.000134	0.00274	CcSEcCtD
Fulvestrant—Dermatitis—Fluorouracil—colon cancer	0.000134	0.00274	CcSEcCtD
Fulvestrant—Paraesthesia—Capecitabine—colon cancer	0.000133	0.00273	CcSEcCtD
Fulvestrant—Headache—Fluorouracil—colon cancer	0.000133	0.00272	CcSEcCtD
Fulvestrant—Dyspnoea—Capecitabine—colon cancer	0.000132	0.00271	CcSEcCtD
Fulvestrant—Nausea—Irinotecan—colon cancer	0.000132	0.0027	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000131	0.00254	CbGpPWpGaD
Fulvestrant—Back pain—Methotrexate—colon cancer	0.000131	0.00268	CcSEcCtD
Fulvestrant—Dyspepsia—Capecitabine—colon cancer	0.000131	0.00267	CcSEcCtD
Fulvestrant—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000129	0.0025	CbGpPWpGaD
Fulvestrant—Decreased appetite—Capecitabine—colon cancer	0.000129	0.00264	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Capecitabine—colon cancer	0.000128	0.00262	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000128	0.00248	CbGpPWpGaD
Fulvestrant—Fatigue—Capecitabine—colon cancer	0.000128	0.00262	CcSEcCtD
Fulvestrant—Constipation—Capecitabine—colon cancer	0.000127	0.0026	CcSEcCtD
Fulvestrant—Pain—Capecitabine—colon cancer	0.000127	0.0026	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—MYC—colon cancer	0.000127	0.00245	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000126	0.00245	CbGpPWpGaD
Fulvestrant—Nausea—Fluorouracil—colon cancer	0.000126	0.00258	CcSEcCtD
Fulvestrant—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.000126	0.00243	CbGpPWpGaD
Fulvestrant—Anaemia—Methotrexate—colon cancer	0.000125	0.00256	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—MYC—colon cancer	0.000124	0.00241	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000123	0.00239	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000122	0.00236	CbGpPWpGaD
Fulvestrant—Vertigo—Methotrexate—colon cancer	0.000122	0.00249	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Capecitabine—colon cancer	0.000121	0.00248	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—colon cancer	0.000121	0.00248	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—colon cancer	0.00012	0.00233	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—CCND1—colon cancer	0.00012	0.00233	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—KRAS—colon cancer	0.000119	0.00231	CbGpPWpGaD
Fulvestrant—Cough—Methotrexate—colon cancer	0.000118	0.00242	CcSEcCtD
Fulvestrant—Urticaria—Capecitabine—colon cancer	0.000118	0.00241	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000118	0.00228	CbGpPWpGaD
Fulvestrant—Abdominal pain—Capecitabine—colon cancer	0.000117	0.0024	CcSEcCtD
Fulvestrant—Body temperature increased—Capecitabine—colon cancer	0.000117	0.0024	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—colon cancer	0.000115	0.00236	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—colon cancer	0.000115	0.00236	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—colon cancer	0.000115	0.00236	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000115	0.00223	CbGpPWpGaD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000114	0.00234	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—HNF4A—colon cancer	0.000113	0.0022	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—colon cancer	0.000113	0.00218	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000113	0.00218	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—EP300—colon cancer	0.000111	0.00214	CbGpPWpGaD
Fulvestrant—Infection—Methotrexate—colon cancer	0.00011	0.00225	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—PIK3CA—colon cancer	0.00011	0.00212	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Capecitabine—colon cancer	0.000109	0.00224	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000109	0.00211	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000108	0.0021	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000108	0.0021	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Methotrexate—colon cancer	0.000108	0.00222	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000108	0.00208	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—CCND1—colon cancer	0.000107	0.00208	CbGpPWpGaD
Fulvestrant—Skin disorder—Methotrexate—colon cancer	0.000107	0.0022	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methotrexate—colon cancer	0.000107	0.00219	CcSEcCtD
Fulvestrant—Asthenia—Capecitabine—colon cancer	0.000106	0.00218	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—colon cancer	0.000105	0.00215	CcSEcCtD
Fulvestrant—Pruritus—Capecitabine—colon cancer	0.000105	0.00215	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—CCND1—colon cancer	0.000105	0.00203	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CTNNB1—colon cancer	0.000104	0.00201	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—EP300—colon cancer	0.000104	0.00201	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	0.000103	0.002	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000103	0.002	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—PPARG—colon cancer	0.000102	0.00198	CbGpPWpGaD
Fulvestrant—ESR1—LKB1 signaling events—TP53—colon cancer	0.000102	0.00198	CbGpPWpGaD
Fulvestrant—Diarrhoea—Capecitabine—colon cancer	0.000102	0.00208	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—HRAS—colon cancer	0.000101	0.00196	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—EP300—colon cancer	0.000101	0.00195	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000101	0.00206	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—colon cancer	9.99e-05	0.00204	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—CCND1—colon cancer	9.93e-05	0.00192	CbGpPWpGaD
Fulvestrant—Paraesthesia—Methotrexate—colon cancer	9.92e-05	0.00203	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—colon cancer	9.85e-05	0.00202	CcSEcCtD
Fulvestrant—Dizziness—Capecitabine—colon cancer	9.81e-05	0.00201	CcSEcCtD
Fulvestrant—Dyspepsia—Methotrexate—colon cancer	9.72e-05	0.00199	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—EP300—colon cancer	9.65e-05	0.00187	CbGpPWpGaD
Fulvestrant—Decreased appetite—Methotrexate—colon cancer	9.6e-05	0.00197	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	9.57e-05	0.00185	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—VEGFA—colon cancer	9.55e-05	0.00185	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Methotrexate—colon cancer	9.54e-05	0.00195	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—colon cancer	9.52e-05	0.00195	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	9.5e-05	0.00184	CbGpPWpGaD
Fulvestrant—Pain—Methotrexate—colon cancer	9.45e-05	0.00193	CcSEcCtD
Fulvestrant—Vomiting—Capecitabine—colon cancer	9.44e-05	0.00193	CcSEcCtD
Fulvestrant—Rash—Capecitabine—colon cancer	9.36e-05	0.00191	CcSEcCtD
Fulvestrant—Dermatitis—Capecitabine—colon cancer	9.35e-05	0.00191	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	9.33e-05	0.00181	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	9.32e-05	0.0018	CbGpPWpGaD
Fulvestrant—Headache—Capecitabine—colon cancer	9.3e-05	0.0019	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	9.25e-05	0.00179	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	9.23e-05	0.00179	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—MYC—colon cancer	9.04e-05	0.00175	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Methotrexate—colon cancer	9.03e-05	0.00185	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	9.03e-05	0.00175	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	9.01e-05	0.00175	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	8.99e-05	0.00174	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—FGFR3—colon cancer	8.96e-05	0.00173	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—AKT1—colon cancer	8.95e-05	0.00173	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—SRC—colon cancer	8.88e-05	0.00172	CbGpPWpGaD
Fulvestrant—Nausea—Capecitabine—colon cancer	8.81e-05	0.0018	CcSEcCtD
Fulvestrant—Urticaria—Methotrexate—colon cancer	8.78e-05	0.0018	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—colon cancer	8.73e-05	0.00179	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—colon cancer	8.73e-05	0.00179	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—MYC—colon cancer	8.61e-05	0.00167	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.6e-05	0.00167	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—ABCB1—colon cancer	8.59e-05	0.00166	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	8.59e-05	0.00166	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—TGFB1—colon cancer	8.59e-05	0.00166	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	8.58e-05	0.00166	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	8.57e-05	0.00166	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.46e-05	0.00164	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—EGFR—colon cancer	8.42e-05	0.00163	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MYC—colon cancer	8.41e-05	0.00163	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TGFB1—colon cancer	8.39e-05	0.00163	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	8.34e-05	0.00161	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—HNF4A—colon cancer	8.29e-05	0.00161	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Methotrexate—colon cancer	8.14e-05	0.00167	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	8.12e-05	0.00157	CbGpPWpGaD
Fulvestrant—Asthenia—Methotrexate—colon cancer	7.93e-05	0.00162	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—colon cancer	7.82e-05	0.0016	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—BRAF—colon cancer	7.77e-05	0.0015	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CDH1—colon cancer	7.61e-05	0.00147	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—HNF4A—colon cancer	7.56e-05	0.00146	CbGpPWpGaD
Fulvestrant—Diarrhoea—Methotrexate—colon cancer	7.56e-05	0.00155	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	7.49e-05	0.00145	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—PPARG—colon cancer	7.48e-05	0.00145	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	7.47e-05	0.00145	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	7.46e-05	0.00144	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	7.31e-05	0.00142	CbGpPWpGaD
Fulvestrant—Dizziness—Methotrexate—colon cancer	7.31e-05	0.00149	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—HNF4A—colon cancer	7.22e-05	0.0014	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.04e-05	0.00136	CbGpPWpGaD
Fulvestrant—Vomiting—Methotrexate—colon cancer	7.02e-05	0.00144	CcSEcCtD
Fulvestrant—Rash—Methotrexate—colon cancer	6.97e-05	0.00143	CcSEcCtD
Fulvestrant—Dermatitis—Methotrexate—colon cancer	6.96e-05	0.00142	CcSEcCtD
Fulvestrant—Headache—Methotrexate—colon cancer	6.92e-05	0.00142	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—colon cancer	6.91e-05	0.00134	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	6.91e-05	0.00134	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ABCB1—colon cancer	6.89e-05	0.00133	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	6.85e-05	0.00133	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.77e-05	0.00131	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—TYMS—colon cancer	6.76e-05	0.00131	CbGpPWpGaD
Fulvestrant—Nausea—Methotrexate—colon cancer	6.56e-05	0.00134	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—PPARG—colon cancer	6.51e-05	0.00126	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	6.35e-05	0.00123	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PPARG—colon cancer	6.29e-05	0.00122	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—colon cancer	6.25e-05	0.00121	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	6.14e-05	0.00119	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—AKT1—colon cancer	5.97e-05	0.00116	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—DLC1—colon cancer	5.95e-05	0.00115	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—colon cancer	5.83e-05	0.00113	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CASP3—colon cancer	5.83e-05	0.00113	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CCND1—colon cancer	5.67e-05	0.0011	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.63e-05	0.00109	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	5.62e-05	0.00109	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LGR5—colon cancer	5.59e-05	0.00108	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—AKT1—colon cancer	5.52e-05	0.00107	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ABCB1—colon cancer	5.51e-05	0.00107	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CDKN1A—colon cancer	5.46e-05	0.00106	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—TYMS—colon cancer	5.41e-05	0.00105	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EP300—colon cancer	5.22e-05	0.00101	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.21e-05	0.00101	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	5.2e-05	0.00101	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	5.19e-05	0.00101	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	5.18e-05	0.001	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	4.95e-05	0.000958	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—VEGFA—colon cancer	4.94e-05	0.000957	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PPARG—colon cancer	4.93e-05	0.000954	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—NRAS—colon cancer	4.86e-05	0.00094	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	4.83e-05	0.000935	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PPARG—colon cancer	4.79e-05	0.000928	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	4.7e-05	0.00091	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	4.65e-05	0.000901	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—colon cancer	4.55e-05	0.000881	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	4.55e-05	0.00088	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—EGFR—colon cancer	4.45e-05	0.000861	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—EGFR—colon cancer	4.43e-05	0.000857	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	4.33e-05	0.000837	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—colon cancer	4.26e-05	0.000826	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	4.21e-05	0.000814	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—KRAS—colon cancer	4.2e-05	0.000814	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—KRAS—colon cancer	4.18e-05	0.000809	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.16e-05	0.000806	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.11e-05	0.000796	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	4.1e-05	0.000793	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ABCB1—colon cancer	4.02e-05	0.000779	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AXIN2—colon cancer	4.02e-05	0.000778	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—TYMS—colon cancer	3.95e-05	0.000765	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PIK3CA—colon cancer	3.84e-05	0.000744	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPARG—colon cancer	3.83e-05	0.000742	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PTGS2—colon cancer	3.77e-05	0.00073	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.77e-05	0.00073	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.76e-05	0.000728	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—colon cancer	3.74e-05	0.000723	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—colon cancer	3.71e-05	0.000719	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.69e-05	0.000714	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—HNF4A—colon cancer	3.64e-05	0.000705	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PPARG—colon cancer	3.6e-05	0.000697	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CA7—colon cancer	3.6e-05	0.000697	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—colon cancer	3.55e-05	0.000688	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	3.48e-05	0.000674	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PPARG—colon cancer	3.28e-05	0.000636	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	3.2e-05	0.000619	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AKT1—colon cancer	3.15e-05	0.000611	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—AKT1—colon cancer	3.14e-05	0.000608	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PPARG—colon cancer	3.14e-05	0.000607	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—EP300—colon cancer	3.14e-05	0.000607	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	3.1e-05	0.000599	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.04e-05	0.000589	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PTGS2—colon cancer	3.01e-05	0.000584	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—colon cancer	2.81e-05	0.000544	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PPARG—colon cancer	2.8e-05	0.000542	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.61e-05	0.000506	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—EP300—colon cancer	2.51e-05	0.000485	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—PIK3CA—colon cancer	2.32e-05	0.000449	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PTGS2—colon cancer	2.2e-05	0.000426	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CHST5—colon cancer	2.18e-05	0.000422	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ODC1—colon cancer	2.18e-05	0.000422	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—colon cancer	2.05e-05	0.000397	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—AKT1—colon cancer	1.95e-05	0.000377	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKT1—colon cancer	1.89e-05	0.000367	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—colon cancer	1.87e-05	0.000362	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PIK3CA—colon cancer	1.85e-05	0.000359	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—EP300—colon cancer	1.83e-05	0.000355	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—colon cancer	1.79e-05	0.000346	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PPARG—colon cancer	1.58e-05	0.000306	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKT1—colon cancer	1.51e-05	0.000293	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—AKT1—colon cancer	1.42e-05	0.000276	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—PIK3CA—colon cancer	1.35e-05	0.000262	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—AKT1—colon cancer	1.24e-05	0.00024	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—FGFR3—colon cancer	1.16e-05	0.000225	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKT1—colon cancer	1.11e-05	0.000214	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—APC—colon cancer	1.07e-05	0.000206	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—BRAF—colon cancer	1e-05	0.000194	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—colon cancer	9.01e-06	0.000175	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CASP3—colon cancer	7.51e-06	0.000145	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCND1—colon cancer	7.31e-06	0.000141	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CTNNB1—colon cancer	7.24e-06	0.00014	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CDKN1A—colon cancer	7.07e-06	0.000137	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EP300—colon cancer	6.73e-06	0.00013	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SRC—colon cancer	6.54e-06	0.000127	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VEGFA—colon cancer	6.37e-06	0.000123	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRAS—colon cancer	6.29e-06	0.000122	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AKT1—colon cancer	6.25e-06	0.000121	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—colon cancer	5.86e-06	0.000113	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TGFB1—colon cancer	5.85e-06	0.000113	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ABCB1—colon cancer	5.76e-06	0.000112	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—EGFR—colon cancer	5.73e-06	0.000111	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TYMS—colon cancer	5.66e-06	0.00011	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KRAS—colon cancer	5.42e-06	0.000105	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PIK3CA—colon cancer	4.98e-06	9.63e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—colon cancer	4.81e-06	9.32e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—colon cancer	4.6e-06	8.91e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKT1—colon cancer	4.06e-06	7.87e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPARG—colon cancer	4.01e-06	7.76e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PTGS2—colon cancer	3.15e-06	6.1e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—EP300—colon cancer	2.62e-06	5.08e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PIK3CA—colon cancer	1.94e-06	3.76e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKT1—colon cancer	1.58e-06	3.07e-05	CbGpPWpGaD
